3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
9
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8
Leukemia, Myeloid, Chronic-Phase
7
Recurrence
5
Leukemia, Lymphocytic, Chronic, B-Cell
5
Breast Neoplasms
5
Multiple Myeloma
4
Lymphoma, Large B-Cell, Diffuse
4
Lung Neoplasms
4
Leukemia, Myeloid, Acute
4
Leukemia
4
Carcinoma, Non-Small-Cell Lung
4
Burkitt Lymphoma
4
Waldenstrom Macroglobulinemia
3
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Lymphoma, Non-Hodgkin
3
Lymphoma, Large-Cell, Anaplastic
3
Lymphoma, Extranodal NK-T-Cell
3
Leukemia, Myeloid, Accelerated Phase
3
Immunoblastic Lymphadenopathy
3
Hodgkin Disease
3
Blast Crisis
3
Squamous Cell Carcinoma of Head and Neck
2
Sezary Syndrome
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Myelodysplastic Syndromes
2
Mycosis Fungoides
2
Interventions
enzalutamide
2
ostarine
1
nilutamide
1
exemestane
1
bicalutamide
1
apalutamide
1
Dasatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Bulbo-Spinal Atrophy, X-Linked
×
Dasatinib
×
Clear all
NCT00918385
2014-10-29
ARS
Duke University
Phase 2
Terminated
57 enrolled
8 charts